FDA staff says late-stage data 'not enough' for Amgen's lung cancer drug

The U.S. Food and Drug Administration's staff reviewers said on Tuesday that Amgen's (AMGN.O) late-stage study may not provide enough evidence of effectiveness for its lung cancer drug, as the company pursues a traditional approval for the treatment.